{"id":830922,"date":"2025-03-27T17:09:30","date_gmt":"2025-03-27T21:09:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/"},"modified":"2025-03-27T17:09:30","modified_gmt":"2025-03-27T21:09:30","slug":"annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/","title":{"rendered":"Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE"},"content":{"rendered":"
\n

MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced that on March 26, 2025, it received notice (the \u201cNotice\u201d) from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE\u2019s Listed Company Manual due to the fact that the Company\u2019s average global market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders\u2019 equity was less than $50 million.<\/p>\n

The Notice does not affect the Company\u2019s business operations or its reporting obligations with the Securities and Exchange Commission, and it does not conflict with or cause an event of default under any of the Company\u2019s material debt or other agreements.<\/p>\n

As set forth in the Notice, as of March 25, 2025, the 30 trading-day average market capitalization of the Company was approximately $37.9 million and the Company\u2019s last reported stockholders\u2019 equity as of December 31, 2024 was $9.3 million.<\/p>\n

The Company has notified the NYSE that it will submit a plan within 45 days of the Notice advising the NYSE of definitive action it has taken, or is taking, to bring it into conformity with Section 802.01B within 18 months of receipt of the Notice. The NYSE will review the Company\u2019s plan and, within 45 days, make a determination as to whether the Company has made a reasonable demonstration of its ability to come into conformity with Section 802.01B within 18 months. If the Company\u2019s plan is not submitted on a timely basis or is not accepted, the NYSE will initiate delisting proceedings. If the NYSE accepts the Company\u2019s plan, the Company\u2019s common stock will continue to be listed and traded on the NYSE during the cure period, subject to the Company\u2019s compliance with the plan and other continued listing standards. The NYSE will review the Company on a quarterly basis to confirm compliance with the plan. If the Company fails to comply with the plan or does not meet continued listing standards at the end of the 18-month cure period, it will be subject to the prompt initiation of NYSE suspension and delisting procedures.<\/p>\n

The Notice has no immediate impact on the listing of the Company\u2019s common stock, which will continue to be \u201cANVS\u201d, subject to the Company\u2019s continued compliance with the plan and other listing requirements of the NYSE. However, the common stock trading symbol will have an added designation of \u201c.BC\u201d to indicate that the status of the common stock is below criteria with the NYSE continued listing standards. The \u201c.BC\u201d indicator will be removed at such time as the Company regains compliance.<\/p>\n

\n Cautionary Note Regarding Forward-Looking Statements<\/strong>
\n
This press release contains, and oral statements made from time to time by our representatives may contain, \u201cforward-looking statements.\u201d Forward-looking statements include statements identified by words such as \u201ccould,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cseeks,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201ccontinues,\u201d \u201cprojects\u201d and similar references to future periods, or by the inclusion of forecasts or projections. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the Company\u2019s ability to develop a plan to regain compliance with the continued listing criteria of the NYSE; the NYSE\u2019s acceptance of such plan; the Company\u2019s ability to execute such plan and to continue to comply with applicable listing standards within the available cure period; risks arising from the potential suspension of trading of the Company\u2019s common stock on the NYSE; regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks regarding our ability to manage inventory or anticipate consumer demand; changes in consumer confidence and spending; our competitive environment; our failure to open new profitable stores or successfully enter new markets and other factors set forth under \u201cRisk Factors\u201d in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. Any forward-looking statement made in this report speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.<\/p>\n

\n
\n About Annovis Bio, Inc.:<\/u>
\n <\/strong>
\n
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company\u2019s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.<\/p>\n

\n
\n Contact:<\/u>
\n <\/strong>
\n
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com<\/a><\/p>\n

\n Investor Contact:<\/strong>
\n
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced that on March 26, 2025, it received notice (the \u201cNotice\u201d) from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE\u2019s Listed Company Manual due to the fact that the Company\u2019s average global market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders\u2019 equity was less than $50 million. The Notice does not affect the Company\u2019s business … <\/p>\n

Continue reading “Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-830922","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAnnovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced that on March 26, 2025, it received notice (the \u201cNotice\u201d) from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE\u2019s Listed Company Manual due to the fact that the Company\u2019s average global market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders\u2019 equity was less than $50 million. The Notice does not affect the Company\u2019s business … Continue reading "Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-27T21:09:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjI5MyM2ODM4MjI5IzIxOTQ4NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE\",\"datePublished\":\"2025-03-27T21:09:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\\\/\"},\"wordCount\":876,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMjI5MyM2ODM4MjI5IzIxOTQ4NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\\\/\",\"name\":\"Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMjI5MyM2ODM4MjI5IzIxOTQ4NTA=\",\"datePublished\":\"2025-03-27T21:09:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMjI5MyM2ODM4MjI5IzIxOTQ4NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMjI5MyM2ODM4MjI5IzIxOTQ4NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/","og_locale":"en_US","og_type":"article","og_title":"Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - Market Newsdesk","og_description":"MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (\u201cAnnovis\u201d or the \u201cCompany\u201d), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), today announced that on March 26, 2025, it received notice (the \u201cNotice\u201d) from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE\u2019s Listed Company Manual due to the fact that the Company\u2019s average global market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders\u2019 equity was less than $50 million. The Notice does not affect the Company\u2019s business … Continue reading \"Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-27T21:09:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjI5MyM2ODM4MjI5IzIxOTQ4NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE","datePublished":"2025-03-27T21:09:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/"},"wordCount":876,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjI5MyM2ODM4MjI5IzIxOTQ4NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/","name":"Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjI5MyM2ODM4MjI5IzIxOTQ4NTA=","datePublished":"2025-03-27T21:09:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjI5MyM2ODM4MjI5IzIxOTQ4NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMjI5MyM2ODM4MjI5IzIxOTQ4NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-inc-receives-continued-listing-standard-notice-from-the-nyse\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/830922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=830922"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/830922\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=830922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=830922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=830922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}